The share price of Apollo Hospital Enterprises exceeded more than 5 percent in the morning session on August 16 after the company reported a combined after-tax revenue (PAT) at Rs 489 crore for the June quarter of the 2021-22 financial year. The health care officer reported a loss of Rs 208 crore in the April-June 2020-21 quarter.
The consolidated revenue for the quarter of June 2021 stood at Rs 3,760 crore compared to Rs 2,171 crore in the first quarter of the previous fund, Apollo Hospitals Group said in a statement on August 13.
The stock was trading at Rs 4,299.25, up Rs 239.05, or 5.89 percent. It affected the 52-week high of Rs 4,319.90. Affected high intraday of Rs 4,319.90 and low intraday of Rs 4,139.45.
The fund was trading at 59,285 shares in comparison with its five-day average of 21,087 shares, an increase of 181.14 percent.
International research company CLSA has improved the stock to better out of sales and raised the target to Rs 4,420 from Rs 2,900 per share. The company has shipped a strong Q1 despite a higher than expected contribution from COVID services. It would take a huge surprise to measure the top driving, reports a CNBC-TV18 report.
“COVID-19-connected services increase EBITDA and profitability. We raise our FY22-24 EBITDA rates by 8-13 percent. A strong quarter for pharmacy and new hospital stay is already very high. .
Credit Suisse has a call above stock and has raised the target to Rs 4,800 from Rs 3,850 per share. It is the view that the inclusion of strategic and financial partners should accelerate the expansion of clients. Enhancing generic medicine could add up to 40 percent of EBITDA offline pharmacy, while the rate of diagnostic growth is strong, it said.
also read : The pandemic beats India’s $ 5 trillion economy with FY25: Economist
